Families of children with a genetic muscle-wasting condition claim NHS failings are stopping them accessing a drug that slows it down.

Families of children with a genetic muscle-wasting condition claim NHS failings are stopping them accessing a drug that slows it down.

The drug Givinostat was made available to patients with Duchenne Muscular Dystrophy through the Early Access Programme last year.

But campaigners say clinical teams lack “the capacity to process the paperwork” to administer it.

Una Farell is from the Hammersmith based charity, Duchenne UK.